Incyte Reports Phase 2 GEOMETRY Mono-1 Trial Of Investigational Medicine Capmatinib Showed 'overall response rate of 72%, 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated NSCLC'